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INTRODUCTION
          An epidemic of Cardiovascular disease (CVD) is a predicted in the Indian 
subcontinent as a result of change in demographics and lifestyle and poor childhood 
nutrition impacting on disease in adult life.1, 2 In contrast to the west the prevalence of 
ischemic heart disease in India has been steadily increasing over the last two decades, 
from around 1-4% to over 10%, these figures are based on survey data but supported 
by clinical impression.3, 4, 5 the prevalence in rural areas is about half that of urban 
populations.6 It is predicted that CVD will be the leading cause of death in india in 
years to come
Asian Indians have higher prevalence of premature ischemic heart disease than 
Europeans, Chinese and Malayas5; this is likely to be influenced by conventional risk 
factors such as smoking, blood pressure and cholesterol levels plus an increasing 
prevalence of insulin resistance and other metabolic abnormalities.6
Reducing CVD and the impact of the epidemic will require extensive public 
health strategies at the population and individual levels. The lack of facilities for 
diagnosis and treatment of CVD and the cost of treatment mean that large sections of 
the Indian populations have poor access to both prevention and treatment,3 one cost 
effective approach, which could achieve substantial benefits within a few years, is
provision of combined Cardiovascular (CV) medication to those at highest risk.
Indications for three classes of treatment (antiplatelet therapy, blood pressure 
lowering and cholesterol lowering) exist among people at highest risk of CVD. 
Individuals with symptomatic coronary or Cerebrovascular Disease or diabetes with 
complications have over a 20% risk of a CV event in the next 5 years.9   
These patient groups are at the highest risk of CVD  and   account for about 
half of all CV deaths and hospitalizations.10 International guide lines  now 
recommend almost all such high risk individuals  receive treatment with each of three 
classes of CV medication namely antiplatelet, blood pressure lowering and cholesterol 
lowering therapies.9, 11, 17  The evidence base for these recommendations is one of the 
most extensive in medical care ,with many tens of  thousands participants in major 
trials of each class of treatment.12
12
Land mark trails recently published, including the heart protection study18 and 
progress 19 definitely show that these treatments should be provided largely 
irrespective of baseline factor levels or concomitant treatments. These and other large 
scale trails such as hope20 and lipid21, 22 as well as overuse of antiplatelet therapy23 
show that the benefits extended to all major subgroups eg: defined by age sex and 
type of vascular disease thus there unequivocal evidence that virtually all people with 
established vascular disease or who are otherwise at high risk would benefit from 
treatment with antiplatelet, blood pressure and cholesterol lowering therapies.24, 25
  
A cross sectional survey of approximately 1,100 residents of two areas in 
Urban South India found that of the 47 individuals with Definite Coronary Artery 
Disease only 23.4% of these were on therapy with blood pressure lowering drugs 
(with only half receiving β–blockers) and (2%) was on a lipid lowering  drugs.5
Comparison of 71 tertiary and secondary centers over  India with data over 4,000 
acute coronary syndrome patients found that at 30 days nearly all were receiving 
antiplatelet agents but less than half were prescribed β –blockers(60% and 51%).28
similarly a study of acute myocardial infarction (MI) showed that Thrombolysis,       
β-blockers and Angiotensin-converting enzyme-I(ACE-I)inhibitors, were used in 
674(63%), 596(47%) and 413(38%) respectively of 1072 patients.27
EUROASPIRE II surveyed CHD patients in across Europe found good levels 
of antiplatelet use, a range of β-blocker use between countries (47-88%) and 
persistent low use of statins (40-60%), although this represented a substantial increase 
in statin use since the previous survey four year earlier.40 A British survey showed that 
less than half of women with a history of myocardial infarction  or stroke were taking 
antiplatelet medication and only one in five were receiving a statin31 a review in Italy 
demonstrated that a third of patients with a history of stroke or transient ischemic 
attack were not on antiplatelet therapy.32A study on patients with established coronary 
disease in  New Zealand found that (personal communication, A Kerr). Only 11% 
were receiving lipid lowering, antiplatelet therapy, an ACE inhibitor and a β-blocker 
(i.e. current guideline recommendations). In a recent Australian general practice study
of over 10,000 participants (professor Chris Reid personal communication) only about 
one third of patients were  receiving guideline – recommended combination of 
medications. 
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Potential to improve adherence with fixed dose combination(polypill) medication
The reasons for treatment gaps are complex and likely to include resistance
(on the part of both physicians and patients) to the cost, complexity and stigmatization 
of prescribing for or more separate CV medications and resultant low adherence, as 
well as poor dissemination and uptake of guidelines .Including dosing more than one 
day .35 Cost can be an important factor36, 37 and patients can delay or omit doses38 and 
not fill prescreptions.37 As strategies for cost reduction. Despite widespread 
perceptions, placebo–controlled trails show that non–adherence for common CV 
medications are rarely due to pharmacological side effects. In long term trials of low 
dose aspirin, blood pressure and cholesterol lowering, Only 1-3% percent of people 
stopped medication due to side effects attributable to the medicines, but a further 10-
25% stopped for other reasons. For example, in PROGRESS 13% of people in the 
active group stopped all treatment over 4 years, but so did 11% in the placebo 
group.19
Simple, low cost combination pills may represent an important opportunity for 
improving provision and adherence of effective CV medications. Encouraging but 
inconclusive results were seen in a systematic review (Connor et al, in press39) of 
randomized trials assessing the effect of combination pills and unit-of-use packing 
compared with the same medications presented as separate pills. Despite very small 
sample sizes in many of the trials (less than half had over 100 participants), tends to 
improvements in adherence and on clinical outcomes were seen in 11  of 14 trials 
including 3 trails of hypertension treatment and one study of combination packing 
conducted in people with diabetes in New Zealand.40
A major cost-effectiveness  analysis conducted for the World Health Report 
clearly showed that absolute risk  based combination treatment is more cost- effective 
then threshold-based  unifactoral approaches (e.g.hypertension treatment )  in all 
world regions and age and sex groups.41 Indeed this strategy appears particularly 
attractive in terms of dollars per disability-adjusted life year (DALY) averted 
compared to a wide range of preventive activities and have the potential to 
substantially reduce CVD at the population level. A strategy of non-personal 
interventions such as salt reduction in food and use of combination treatment based on 
absolute risk has the potential to reduce CV events by more than 50%.41       
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Hypertension: 42
This is called as high blood pressure, is a medical condition in which the blood 
pressure is chronically elevated.
Types of Hypertension:
     Physicians classify the different kinds of hypertension based on their causes 
and characteristics.
1. Primary (essential) hypertension.
2. Secondary   hypertension.
Primary (essential) Hypertension:
It indicates that no specific medical cause can be found to explain patient’s 
condition. About 95% of hypertension is essential hypertension. Primary hypertension 
is caused by variety of factors.
Isolated Systolic Hypertension:
This is one of the types of primary hypertension. As people age their arteries 
tend to lose elasticity and become less able to accommodate blood surges. The 
damage created in the vessel lining when blood flow through the arteries at high 
pressure can accelerate plaque build up, this lead to atherosclerosis this can elevate 
systolic blood pressure, while diastolic blood pressure stays in the normal range. This 
is called isolated systolic blood pressure.
Secondary Hypertension:
It is indicates that the high blood pressure is a result of secondary to another 
condition such as kidney disease or tumors (Adrenal adenoma or 
Pheochromocytoma).
Causes of secondary hypertension are:
                                          
 Renal artery stenosis.
 Hyperaldosteronism.
 Hyperthyroidism.
 Pheochromocytoma.
 Caushing’s syndrome and Coarctation of the aorta.
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Blood pressure Measurement: 43
Blood pressure is measured in the form of two numbers, namely, the systolic 
and the diastolic blood pressure. It is written as 120/80, where 120 is the systolic 
blood pressure and 80 is the diastolic blood pressure. Systolic pressure is the pressure 
of the blood when heart beats. This is the highest pressure exerted by the blood. 
Diastolic pressure is the pressure of the blood when the heart rests between beats this 
is the lowest pressure exerted by the blood.
There are two ways of measuring blood pressure.
1) The Auscultatory method.
2) The Oscillometric method.
1. Auscultatory method:
In this method, a Stethoscope and a sphygmomanometer are used. In this 
method, an inflatable cuff is placed around the upper arm, at roughly the same vertical 
height as the heart. The cuff is attached to mercury. The cuff is inflated manually by 
squeezing a rubber bulb repeatedly until the artery is completely occluded.
The pressure in the cuff is slowly reduced. A whooshing or pounding sound is 
heard. The pressure at this point is called systolic pressure. Then the pressure in the 
cuff is further reduced, till no sound is heard. The pressure at this point is called 
diastolic blood pressure. Both these pressures are record to find out the accurate blood 
pressure.
2. Osillometric method:
This method is similar to the auscultatory method functionally. It is used in 
long term measurement as well as in clinical practice. The cuff in this type of 
monometer comes with an electronic pressure sensor fitted in the cuff to detect the 
blood flow. In this method, the mercury manometer is fitted on the wrist, elevated to 
the height of the heart, though the upper arm is always preferred. The cuff is inflated 
and released by an electrically operated pump, which then gives out a numerical read 
out of the blood pressure. Oscillometric measurement does not require much skill and 
is easy to use by even non trained staff and patient themselves.
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Regulation of blood pressure: 44
Classification of Hypertension for Adults according to JNC-VII45:
Condition Systolic Blood pressure Diastolic Blood pressure
Normal < 120 mm of Hg  and < 80 mm of Hg
Prehypertension 120-139 mm of Hg  (or)
80-89 mm of Hg
Hypertension
Stage-I (Moderate)
140-159 mm of Hg (or) 90-99 mm of Hg
Hypertension
Stage-II (severe)
≥ 160 mm of Hg (or) ≥ 100 mm of Hg
Blood pressure
Cardiac 
out put
Stroke 
volume 
Systemic vascular 
resistance
Heart 
rate
PSNS 
SNS
Catecholamines
Venous 
tone
Contractility Preload
Intra vascular 
volume
Direct 
interaction 
Circulatory 
regulators
Local 
regulators
A.T II
Na+/H2O 
retention
1 -RT C.A
Thirst
Prostacyclins
N.O
O2
A.T II
Endothelin
Adenosine
H+
SNS
Aldosterone
ADH
Natriuritic peptides
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Pharmacological treatment of Hypertension:46
S.No. Category Drug classification Drugs
1. Diuretics a)Thiazide diuretics
b)Loop diuretics 
c) K+-sparing diuretics
Chlorthiazide,
Hydrochlorothiazide 
Furosemide, 
Ethacrynic acid,
Torsemide,
Amiloride,
Spiranolactone, Triamterene.
2. Sympatholytics a) CNS sympathetic out 
flow blockers.
b) Ganglionic blockers
c) Post Ganglionic        
adrenergic nerve 
terminal antagonists
d) 1 -Adrenergic 
blockers
e) 1 -Adrenergic 
blockers
Clonidine, Methyldopa.
Trimethophan, 
Hexamethonium
Gunethidine,
Reserpine 
Prazosin , 
Terazosin(selective)
Phentolamine,  Phenoxy-
benzamine (Non selective)
Atenolol, Timolol, Pindolol
3. Vasodilators a) Ca2+ channel blockers.
b) K+ channel openers.
c) Arteriolar Venular 
vasodilators 
Nefidipine, Amilodpine
Minoxidil, Hydralazine.
Sodium nitroprusside.
4. RAAS inhibitors a) ACE inhibitors
b) Renin inhibitors 
C) AT1 antagonists
Captopril, Ramipril, Enalapril, 
Lisinopril.
Β-blockers.
Losartan,
Valsartan
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Mechanism action of Antihypertensive drugs: 46
Renin-Angiotensin Aldosterone System: 47
Renin-Angiotensin-Aldosterone System (RAAS) plays an important role in 
regulating blood volume and systemic vascular resistance, which together influence 
cardiac output and arterial pressure.
Blood pressure
Cardiac 
out put
Stroke 
volume 
Systemic vascular 
resistance
Heart 
rate
 -antagonist 
Calcium channel 
blockers
Venous 
tone
Contractility Preload
Intra vascular 
volume
Direct 
interaction 
Circulatory 
regulators
Local 
regulators
Na+/H2O 
retention
1 -antagonists 
Central 2
antagonists
Endothelin 
antagonists
Sodium 
nitroprusside 
e ACE 
inhibitors
A.T I 
antagonists
 -antagonist 
Calcium channel 
blockers
1 -antagonists 
Central 2
antagonists
A.T I antagonists
ACE inhibitors
1 - antagonists
Sodium nitroprusside 
ACE inhibitors
A.T I antagonists 
Diuretics 
ACE inhibitors
A.T I antagonists
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Renin is a proteolytic enzyme that is released from the kidneys, its release is 
stimulated by the:     
 Sympathetic nerve activation (acting via β1 adrenoceptors).
 Renal artery Hypotension (caused by Systemic Hypotension or Renal artery 
stenosis).
 Decreased Sodium delivery to the distal tubules of the kidney.
When Renin is released in to the blood, it acts upon a circulating substrate, 
Angiotensinogen that undergoes Proteolytic cleavage to form the Decapeptide 
Angiotensin I. Vascular endothelium, particularly in the lungs, has an enzyme, 
Angiotensin converting enzyme (ACE) that cleaves of two amino acids to form the 
Octapeptide, Angiotensin II (AII).
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Functions of Angiotensin II:
 Constricts resistance vessels (via AII, AT1 receptors) there by increasing 
systemic vascular resistance and arterial pressure.
 Act on the adrenal cortex to release Aldosterone, which in turn acts on the 
kidneys to increase sodium and fluid retention.
 Stimulates the release of vasopressin (anti diuretic hormone, ADH) from the 
Posterior pituitary, which increases fluid retention by the kidneys.
 Stimulates thirst centers within the brain.
 Facilitates Norepinephrine release from sympathetic nerve endings and 
inhibits Norepinephrine re-uptake by nerve endings, there by enhancing 
sympathetic adrenergic function.
 Stimulates cardiac hypertrophy and vascular hypertrophy.
Manipulation of this pathway is very important in treating hypertension.    
ACE inhibitors, AII receptor blockers and Aldosterone receptor blockers are used to 
decrease arterial pressure, ventricular after load, blood volume and hence ventricular 
preload, as well as inhibit and reverse cardiac and vascular hypertrophy.
Adverse effects of ACE inhibitors: 48
Common adverse drug reactions:
 Hypotension,
 Cough,
 Hyperkalemia
 Headache
 Dizziness
 Fatigue
 Nausea
 Renal impairment
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A persistent Dry cough is a relatively common adverse effect believed to be 
associated with the increases in Bradykinin levels produced by ACE inhibitors.
Rash and taste disturbances are infrequent with most ACE inhibitors.
Renal impairment is a significant adverse effect of all ACE inhibitors. The reason for 
this is still unknown. ACE inhibitors may cause Hyperkalemia. Suppression of 
Angiotensin II leads to a decrease in Aldosterone levels. Since Aldosterone is 
responsible for increasing the excretion of potassium, ACE inhibitors ultimately cause 
retention of potassium. A severe allergic reaction can occur that rarely can affect the 
bowel wall and secondarily cause abdominal pain. This "Anaphylactic" reaction is 
very rare as well. Some patients develop Angioedema due to increased Bradykinin 
levels.
Dyslipidemia (Hyperlipidemia) 49:
It is defend as an abnormality in lipid metabolism leads to increased elevation 
of disorder of lipoprotein metabolism, including lipoprotein over production or 
deficiency. Dyslipidemia may be manifested by elevation of the total cholesterol, the 
"bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, 
and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration 
in the blood.
Dyslipidemia can be divided into,
1. Primary Hyperlipidemia 
2. Secondary  Hyperlipidemia 
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Primary Hyperlipidemia:
S.No. Disease Characteristic lipid profile
1.
a.
b.
c.
d.
Primary Hypercholesterolemia
Familial hypercholesterolemia
Familial defective ApoB100
Autosomal  recessive  
hypercholesterolemia
Polygenic Hypercholesterolemia
↑↑LDL.
↑↑LDL.
↑LDL.
↑cholesterol
2.
a.
b.
c.
Primary Hypertriglyceridemia
Familial Hypertriglyceridemia
Familial lipoprotein lipase deficiency
Apo CII deficiency
↑TG, ↑VLDL, ↓HDL.
↑↑ TG
↑↑ TG
3.
a.
b.
Mixed Hyperlipidemia
Familial combined Hyperlipidemia 
Familial Dysbetalipoproteinemia
↑TG, ↑LDL, ↓HDL
↑TG, ↑LDL, ↑cholesterol, ↑remnants
4.
a.
b.
c.
d.
e.
f.
Disorders of HDL metabolism
Polygenic Low HDL
Familial Hypoalphalipoproteinemia
Familial Apo-AI deficiency
Tangier deficiency
Fisheye disease
LCAT deficiency
↓HDL
↓HDL
↓HDL
↓HDL
↓HDL
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Secondary Hyperlipidemia:
                                 Secondary hypertension is attributed to some other reason 
like, Diabetes mellitus, Hypothyroidism, Chronic Renal failure, Glucagon storage 
disease, stress, etc.,
Optimal, Borderline, and high levels for each component: 50
SOURCE: National Cholesterol Education Program (NCEP) Adult Treatment panel 
III (ATPIII) approach to Dyslipidemia.
Lipoproteins and Dyslipidemia: 51
                                          Lipoproteins are macromolecular structures 
aggregates that transport Triglycerides and Cholesterol in the blood. Circulating 
lipoproteins can be differentiated on the basis of Density, size, and protein content
They are:
 Chyolomicrons (CM)
 Very low density Lipoproteins (VLDL)
 Intermediate Low Density Lipoproteins (IDL)
 Low Density Lipoproteins (LDL)
 High Density Lipoproteins (HDL)
ELIMENT OPTIMAL BORDERLINE HIGH RISK
LDL cholesterol <100 130-159 160+
HDL cholesterol >60 35-45 <35
Triglycerides <150 150-199 >200
Total cholesterol <200 200-239 >240
Cholesterol to HDL 
ratio
<4 5 >6
24
S.
NO.
Parameters CM VLDL IDL LDL HDL
1 Density (g/ml) <0.95 0.95-1.006 1.006-1.019 1.019-1.063 1.063-1.21
2. Diameter (nm) 75-1200 30-80 25-35 18-25 5-12
3. Total lipid (%wt.) 98 90 82 75 67
4. Composition(% dry wt.)
a. Protein 2 10 18 25 33
b. Triglycerides 83 50 31 9 8
c.
Unesterified cholesterol and 
cholesterol esters
7 22 29 45 30
5. Phospholipids (%wt. Lipid) 7 18 22 21 29
6. Major Apolipoprotiens
B48, AI, AIV, 
E, CI, CII, CIII
B100, E,CI, CII,CIII B100, E, CI, CII, CIII B100
AI, AII, E, 
CI, CII, CIII
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Diagnosis:
       Serum lipid profile is used for the measuring total cholesterol, TG, and     
HDL-cholesterol and calculated LDL-cholesterol and VLDL.
Treatment: 52
      Goals for Lipid Lowering were established in the National cholesterol 
education program adult treatment panel III (ATP).  Guidelines which provide target 
LDL levels.
Treatment strategies:
                            1. Dietary therapy
                             2. Exercise and stress reduction.
                             3. Drug therapy
a. Statins- HMG COA reductase inhibitors:
                                                Lovastatin
                                                Simvastatin 
                                                Pravastatin 
                                                Atorvastatin 
                                                Rusavastatin 
b. Bile acids Binding resins:            
                     Cholestyramine
                     Colespitol
c. Fibrates and derivatives :
                       Benzfibrate
                       Clofibrate
                       Gemfibrozil
                       Ciprofibrate
d. Nicotinic acid
           
e. Fish oil 
f. Cholesterol absorption inhibitor: Ezeimibe
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Mechanism of action of statins:
Acetyl CoA
HMG-COA REDUCTASE
INHIBITORS    X                            HMG-COA REDUCTASE       
       
   Cholesterol
Cholesterol levels intracellularly
      More LDL receptors are expressed and
         Increased LDL uptake and clearance         
ADVERSE EFFECTS OF STATINS: 52
                                                   "Muscle problems are the best known of statin 
drugs' adverse side effects," said Golomb. "But cognitive problems and peripheral 
neuropathy, or pain or numbness in the    extremities like fingers and toes, are also 
widely reported." A spectrum of other problems, ranging from blood glucose 
elevations to tendon problems, can also occur as side effects from statins.
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LITERATURE REVIEW
Raia JJ, et al., Done comparative review on angiotensin-converting inhibitors, are 
capable of lowering blood pressure primarily by promoting vasodilation and reducing 
intravascular fluid volume. Captopril, is an active ACE inhibitor in its orally 
absorbable parent form. In contrast, enalapril must be deesterified in the liver to the 
metabolite enalaprilat in order to inhibit the converting enzyme; this account for its 
delayed onset of action. Lisinopril does not require metabolic activation to be 
effective; however, a slow and incomplete absorption pattern explains the delay in 
onset of activity.53     
Tendera M, et al., studied role of antiplatelet drugs in the prevention of 
cardiovascular events in variety of clinical conditions, such as myocardial infarction, 
raise stroke and cardiovascular death. Both European and American guidelines 
recommend the use of antiplatelet drugs in patients with established coronary disease 
and other atherosclerotic disease. In high risk patients, such as those with post acute 
myocardial infarction (AMI), ischemic stroke or transient ischemic attack, and 
patients with stable or unstable angina, peripheral arterial occlusive disease or atrial 
fibrillation, antiplatelet treatment may reduce the risk of a serious cardiovascular 
event by approximately 25%, including reduction of non-fatal myocardial infarction 
by 1/6, non fatal stroke by 1/4 and cardiovascular death by1/6. Aspirin has been 
studied and used most extensively. It may exert its beneficial effect not only by acting 
on platelets, but also by other mechanisms, such as preventing thromboxane A2 
(TXA2) induced vasoconstriction or reducing inflammation. Experimental data show 
that low dose aspirin may suppress vascular inflammation and thereby increase the 
stability of atherosclerotic plaque.54   
Teo KK, et al., evaluated long term treatment with angiotensin converting enzyme 
(ACE I) inhibitors in the presence or absence of aspirin. They used the peto-yusuf 
method to undertake a systemic overview of data for 22060 patients from six long 
term randomised trials of ACE inhibitors to assess whether aspirin altered the effects 
of ACE inhibitor therapy on major clinical outcomes (composite of death, myocardial 
infarction, stroke, hospital admission for CHF, or revascularization). ACE inhibitor 
therapy significantly reduced the risk of the major clinical outcomes by 22% 
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(p<0.0001), with clear reductions in risk both among those receiving aspirin at 
baseline (odd ratio 0.80, 99% CI 0.73 - 0.88) and those who were not (0.71, 99%              
CI 0.62 - 0.81).55
Oates JA. Studied that is Antagonism of Antihypertensive Drug Therapy by Non 
steroidal Anti-inflammatory drugs. Certain non steroidal anti-inflammatory drugs 
antagonise the action of antihypertensive therapy. Indomethacin has been shown to 
abrogate the antihypertensive effect of beta-adrenergic receptor blockers, diuretics, 
Angitensin converting enzyme inhibitors and several antihypertensive drug 
combinations and the accumulated evidence on Piroxicam indicates that it also raises 
arterial pressure in treated patients. In contrast, Sulindac and aspirin do not reverse the 
effects of antihypertensive drugs and currently available data indicate that they are the 
safest Cyclooxygenase inhibitors for use in hypertensive patients.56
Musial J, et al., evaluated treatment with Simvastatin and low dose aspirin depress 
thrombin generation in patients with coronary heart disease and borderline–high 
cholesterol levels. They investigated whether in patients with borderline–high 
cholesterol levels who have been already taking aspirin, additional treatment with 
Simvastatin would affect thrombin generation. Seven day treatment with low dose 
aspirin decreased thrombin generation exvivo only in patients with total cholesterol   
≤ 5.2 mmol/l, in patients with higher cholesterol levels aspirin had no effect. In these 
patients, already taking low dose aspirin, additional three month Simvastatin 
treatment resulted in a reduction of thrombin generation. This demonstrates that low–
dose aspirin depress thrombin generation only in subjects with desirable blood 
cholesterol levels, while in others, with borderline–high cholesterol, thrombin 
formation is being reduced following addition of Simvastatin.57
Sposito AC, et al., studied on additional reduction in blood pressure after cholesterol-
lowering treatment by statins (Lovastatin or Pravastatin) in Hypercholesterolemic 
patients using angiotensin–converting enzyme inhibitors (Enalapril or Lisinopril). 
Blood pressure reduction was compared between patients receiving angiotensin 
converting enzyme inhibitors alone and patients receiving these medications plus 
statins after three months of dietary intervention. Although BP was similarly reduced 
at 4th week, the statin treated group had a greater reduction in BP and cholesterol 
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lowering with statins and Angiotensin – Converting enzyme inhibitor treatment for 
hypertensive patients.58
Paoletti R, et al., studied on pharmacological interactions of statins. HMG-CoA 
reductase inhibitors are effective in reducing the risk of coronary events and are 
generally very well tolerated, these are biotransformed in the liver primarily by 
cytochrome  P450(CYP)3A4 clinical experience has shown that the risk of adverse 
effects, such as myopathy, myositis, and rhabdomyolysis have been reported. In some 
statins may have lower adverse drug interaction potential then others, which is an 
important determinant of safety during long term therapy.59
Skoularigis J, et al., evaluated efficacy of low dose (12.5 to 25mg) 
hydrochlorothiazide was evaluated by ambulatory blood pressure monitoring in 19 
mild to moderate hypertensive (mean 12-h diastolic BP>or 90 mm hg and <115 mm 
Hg) south African black patients. After a 3 week placebo run–in period, HCTZ was 
administered for 8 weeks as Monotherapy. The mean day time ABPM was only 32% 
patients achieved BP control. 24-h BP load fell from 69% at baseline, to 53% with 
12.5 mg HCTZ and 47% with 25 mg HCTZ daily there were no side effects but the 
increase of HCTZ to 25 mg daily was followed by adverse changes in serum 
potassium levels. It is concluded that low dose of HCTZ Monotherapy has only a 
moderate effect on the BP control. And 24-h BP loads while the higher 25 mg dose is 
associated with significant decrease in serum potassium level.60
Galan L, et al., studied on cardiac cellular actions of hydrochlorothiazide. Long term 
treatment, Thiazide diuretics such as Hydrochlorothiazide lower blood pressure by 
decreasing peripheral vascular resistance rather than by their diuretic effect. This 
action has been attributed to the opening of Ca2+ activated K+ channels in vascular 
smooth muscle cells.61
Shaw E, et al., Discussed on factors associated with non compliance of patients 
taking antihypertensive medications, poor adherence to drug therapy decreases the 
effectiveness of antihypertensive treatment  patient must take  more than 80% of their 
antihypertensive drugs to maintain the adequate blood pressure control. Pilot study 
was conducted in which a questionnaire and contributing was devised and 
administered to a random sample of 243 hypertensive patients of the adult ambulatory 
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care clinic at Methodist Hospital of Indiana. Ninety eight patients completed the 
telephone survey. Demographic review was obtained from chart review.62
The results indicated that 30-46% of the patients were non compliant with their 
antihypertensive drug regimens. Factors found to be associated non compliance were 
employment (P=0.0077), use of home remedies (P=0.0043), age (P=0.0165), 
experience of the side effects (P=0.0051), level of concern with missed doses 
(P=0.0043 and cost (P=0.014). The incidence of non compliance in this pilot sample 
is lower than the estimated 50% noncompliance rate of published data.
Gradman AH, et al., evolving strategies for the use of combination therapy in 
hypertension, two thirds of patients with hypertension require more then one drug to 
achieve goal blood pressure some combinations exhibit side effect neutralization in 
which side effects associated with one drug are neutralized by a second agent. Fixed 
dose combinations reduce the no of pills and simplifying the treatment regimen. 
Because volume overload is common, low dose diuretics are often included in drug 
combinations. Combination of diuretics with potassium sparing diuretics, Angiotensin 
Converting Enzyme Inhibitors, Angiotensin receptor blockers, and b-blockers are use 
full in treating large segments of the hypertension population.63
Waeber B, et al., studied on combined treatment with Captopril, Hydrochlorothiazide 
and Pravastatin in dyslipidemic hypertensive patients. Design: the patient were 
followed for 16 weeks and asked to comply with a lipid lowering diet for the whole 
period. Captopril 50mg/once daily was administered alone for the first 4 weeks 
.Hydrochlorothiazide, 25 mg/day, was added after 4weeks if required. Pravastatin 
(20mg/day) was started at the 8th week of the study and its dose was doubled 4 weeks 
later if needed. Determination of blood pressure, circulating levels of Total 
Cholesterol, HDL-cholesterol and Triglycerides, and blood chemistry for safety 
monitoring. Results: At the end of the trail 75.1% of patients of their diastolic blood 
pressure 90 mmHg and 43.5% a total cholesterol is <6.5 mmol/l the overall 
incidence of adverse events was 21.7% leading to withdrawal in 10.9% of the total 
number of patients. The combined treatment had no deleterious effect on safety 
variables. Conclusion: Captopril, Hydrochlorothiazide and Pravastatin are effective 
and well tolerated medications to treat dyslipidemic hypertensive patients.64
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SCOPE OF THE STUDY
The world Health Report showed the substantial and previously under-
estimated impact of known risks, such as high blood pressure and cholesterol, in 
causing cardiovascular disease. More than half of all cardiovascular disease burdens 
can be attributed to blood pressure and cholesterol they are leading risks to health in 
all developed countries and are increasingly important in developing countries.65
The reasons for treatment gaps are complex and likely to include resistance 
(on the part of both physicians and patients) to the cost, complexity and stigmatization 
of prescribing for more separate CV medications and resultant low adherence, as well 
as poor dissemination and uptake of guidelines. Including dosing more than one day.35
Cost can be an important factor, 36, 37 and patients can delay or omit doses38 and not 
fill prescriptions.
International guidelines now recommend almost all such high risk individuals 
receive treatment with each of three classes of CV medication, namely antiplatelet, 
blood pressure lowering and cholesterol lowering therapies.9, 11, and 17  
A combination pill taken once daily has the ability to address many of these 
issues: the use of multiple drugs might be more acceptable if they were to be 
combined into a single pill containing four categories of drugs, for example, aspirin, 
two categories of antihypertensive drugs and a statin, and taken once a day. The use 
of single pill could well encourage patients to adhere to treatments as well as seriously 
reduce the cost of the drugs. The use of combination pill could be considered and 
evaluated in patients suffering from all other cardiovascular conditions.66
Interventions to lower blood pressure, serum cholesterol, and other risk factors 
also reduce the cardiovascular disease. Randomised  trails show that drugs to lower 
three risk factors- low density lipoprotein (LDL) cholesterol, Blood pressure ,and 
platelet function (with Aspirin) reduce the incidence of cardiovascular events.             
A strategy to simultaneously reduce 3 cardiovascular risk factors (low density 
lipoprotein cholesterol, blood pressure and platelet function) has been recommended 
recently based on meta analysis of randomised trails and cohort studies of 
antihypertensive drugs and statins and a Meta analysis of 15 trails of low dose        
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(50-125 mg/Day) Aspirin. The formulation, which met the  objectives, had a statin 
(for example Atorvastatin or Simvastain); blood pressure lowering drugs (for 
example, a Thiazide, β-blocker and an Angiotensin converting enzyme inhibitor), 
each at half standard dose and aspirin (100mg).  It was estimated that the combination 
would reduce MI,Stoke & cardio vascular death by 75% in secondary prevention.
Hence the company has developed a fixed dose combination of a statin 
(Simvastatin), an antiplatelet agent (Aspirin), an ACE-inhibitor (ramipril) and a 
Diuretic (Hydrochlorothiazide).74  
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OBJECTIVE
To evaluate the fixed dose combination of Simvastatin, Aspirin, 
Hydrochlorothiazide, ramipril and atenolol results in lowering blood pressure and 
cholesterol levels and improved adherence in patients with at least one Cardiovascular 
risk factor such as Hypertension and Dyslipidemia or Coronary Artery Disease.
Drug name  - polycap
(cadila pharmaceuticals)
Aspirin   - 100mg
Atenolol  - 50mg
Hydrochlorthiazide   - 125mg
Ramipril  - 5mg
Simvastatin – 20mg 
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METHODOLOGY
Study Design and Setting:
The study was prospective open labeled 12 weeks. This study was conducted 
in KMCH Hospital Coimbatore.
Ethical considerations: 
The ethical committee in the Institution approved the study process. The 
ethical committee will be provided with the reports and the progress.
Identification of eligible patients:
The patients under  study will be included, males and females aging between 
18-75 years with mild to moderate hypertension as suggested by JNC-VII [139/89 
mm of Hg and  180/110 mm of Hg] and along with abnormal lipid profile LDL-C 
130 mg/dl or LDL-C >100 mg/dl with CAD equivalents  (CAD - Coronary artery 
disease will be diagnosed on patients history/ ECG/Angiogram; Coronary artery 
disease Equivalents are diabetes mellitus, abdominal aortic aneurism, symptomatic 
carotid artery disease). 
Eligibility:
Inclusion criteria:
1. Adults Male or Female age 18 – 75 years.
2. Patients with at least one risk factor for cardiovascular disease namely 
hypertension  139/89 mm of Hg and  180/110 mm of Hg according to       
JNC-VII guidelines and lipid profile LDL-C 130 mg/dl or LDL-C >100 mg/dl 
with CAD Equivalents or patient with coronary artery disease or high 
cardiovascular risk factors. At the screening visits.
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Exclusion Criteria:
The following patients will be excluded:
1. Contraindication /intolerance (e.g.Asthama, peripheral vascular disease for 
Atenolol) to any of the components of the combination pill.
2. The physician is of the opinion that changing a patient’s medication would put 
the patient at risk (e.g. heart failure, high dose β - blocker required to manage 
anginal symptoms)
3. Acute medical conditions/surgeries
4. Medical/psychiatric conditions likely to hinder trail process
5. Lactating and pregnant women.
6. Women of reproductive age, not practicing contraception.
7. Hepatic Dysfunction
8. Renal Dysfunction.
9. Unwilling to give informed consent.
Withdrawals and Dropouts:
A subject may be withdrawn from therapy on account of development of an 
intolerable adverse event.
Study Medication and Dosing
The study for two combinations in tablets form, 
                                            Combination Pill
Low Dose Medium Dose
Aspirin                                   100mg Aspirin                                  100mg
Hydrochlorothiazide             12.5mg Hydrochlorothiazide             12.5mg
Simvastatin                            10mg Simvastatin                            20mg
Ramipril                                  5mg Ramipril                                10mg
Atenolol                                 50mg Atenolol                                  50mg
Low Dose pill taken once daily increased to medium dose, if necessary after 
therapy of 4 weeks, if no improvement or worsening of both LDL-C or/and blood 
pressure (systolic/diastolic) measurements. If there is improvement in both LDL-C 
and BP (systolic and diastolic), keep the low dose for next 8 weeks. 
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All patients who develop dry irritating cough in the 1st 4 weeks of combination 
pill therapy shall be withdrawn from the study.
Tablets will be checked to ensure they will not exceed their expiry date at any 
stage of their prescription to subjects. They will then be dispensed to the patients for 
12 weeks they will then be placed in number coded containers.
Methodology:
           Eligible patients will have a copy of the Ethics Committee approved 
patient information sheet placed in the medical record. The study will be explained
during the clinical consultation. After the explanation the subject will be provided the 
patient information sheet and Informed Consent Form (ICF). The subject will be 
asked to take this away with them and arrangements will be made to follow up via a 
telephone call. If the subject agrees to participate, they will sign the consent form with 
an independent person signing as a witness to this process.
In the next step, the selected patients details are maintained separately for 
recording the screening parameters (Blood Pressure, LDL-Cholesterol, Total 
Triglycerides, Heart Rate, Brief details of the patient, date of onset of study, 
Screening details from baseline visit to 4th visit, doses of the drugs given to the 
patients, Adverse reactions of the drug if any. All the adverse reactions should be 
follow-up either to resolution or to a point where no further improvement is expected.
Visit schedule:
The selected eligible patients who had given the ICF are subjected for 
screening of blood and urine samples which were sent for the baseline safety 
investigations.
The patients are advised to visit the Hospital in 4 visits.
Visit-1 for baseline screening (Day 1), 
Visit-II in 4th week from baseline screening date,
Visit-III in 8th week from baseline screening date,
Visit-IV in the 12th week from baseline screening date.
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Screening visit:
             Only those patients willing to give informed consent will be recruited. 
The patient will be assessed for presence of inclusion and absence of exclusion 
criteria. Selected patients will have their serum and urine samples sent for base line 
safety investigations and asked to report on the next OPD date, when the results are 
expected to be ready.  Pulse rate and supine blood pressure will be measured. The 
laboratory values of hematology, biochemistry with serum and urine, platelet 
aggregation, ECG, 2-D-Echocardiography investigated for baseline parameters in 
subjects.
Day 1: start of therapy:
Patients receive combination polypill (low dose) daily drug regimen for 12 
weeks.
Week 1-4: once –a-week visit:
All patients who develop Dry irritating cough in the 1st 4 weeks of 
combination pill therapy shall be withdrawn from the study. Supine blood pressure 
will be measure by auscultatory method on the day of follow-up in all patients and 
change if any observed.
Week 4:
Subjects will be questioned for adverse events and the laboratory values of 
serum biochemistry, ECG, 2-D-Echocardiography investigated for the efficacy, safety 
and tolerability. Pulse rate and supine blood pressure will be measured. If the blood 
pressure is reduced with Low dose, continue with low dose. If the blood pressure is 
not reduced with low dose increased to medium dose.   
Week 6 and 8, 12: 
Subjects will be questioned for adverse events and the laboratory values of 
serum biochemistry, ECG, 2-D-Echocardiography investigated for the efficacy, safety 
and tolerability. Pulse rate and supine blood pressure will be measured in all the three 
visits.
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The patients will receive the tablets in Visit-I, Visit-II, and Visit-III for each 4 
weeks respectively. The patients are advised to report in the next visit schedule dates.
At each of the visit schedule dates, patients are advised to fast for 12hrs and then the 
patient’s blood and urine samples will be screened. 
The patients will enquire about any adverse reactions or any inconvenience 
while under the study in every visit.
Efficacy variables:
                   In order to determine the efficacy of the drug combination the 
principle parameters are observed along with other parameters.
The parameters with their normal values includes, 
Blood Pressure 120/80 mm of Hg, 
LDL-cholesterol <100 mg/dl, 
Total triglycerides < 200 mg/dl, 
Heart Rate 60-70 beats/min.
Safety Variables:
The other parameters with their normal values includes,
SGOT and SGPT levels 0-65 mcg/L, 
Serum creatinine levels 21-232 mcg/L
Serum electrolytes level
         Na+ levels   135 – 145 mmol /L
K+ levels      3.5 - 5.1 mmol /L
Cl- levels       95 – 106 mmol /L 
Data analysis:
The major parameters to assess the efficacy of the drug combinations are 
blood pressure i.e., systolic and diastolic blood pressure and LDL-cholesterol, and 
Total Triglycerides levels in 4 visits were evaluated by using ANOVA. The 
comparative significance is tested and should be less than 0.05.
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Adherence to Study Medication:
Study visits are conducted every four weeks and as a consequence, sufficient 
medication is included in the container to last for this interval. However as a 
crosscheck of the subject’s adherence to drug therapy, each container has 28 tablets 
placed in it for each study visit and the subjects are not informed that the containers 
have additional tablets. At each study visit the subject is required to return the 
container. Two separate tablet counts are then conducted one by the study by the
coordinator. This enables a check on adherence to therapy by calculating the 
difference between 28 and the days of therapy and comparing this with number of 
tablets left in the container.
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DRUG PROFILE
Simvastatin67: 
           Simvastatin is a lactone Prodrug which is metabolized after oral 
ingestion to the Dihydroxy open acid form. Which inhibits 3-hydroxy-3methylglutaryl 
coenzyme A (HMG-CoA) Reductase? An enzyme that catalyzes than early rate 
limiting step in the biosynthesis of cholesterol.
Clinical Pharmacology:           
             Simvastatin is ﻻ-lactone obtained by chemical modification of 
Lovastatin. Hydrolysis of the lactone by esterase results in the Dihydroxy open acid 
originally designed by the manufacturer as L-654.969.  Now known as Simvastatin 
Acid or S V A .Which is the active form of the compound. This active metabolite is a 
competitive inhibitor of HMG-CoA reductase. A key rate-limiting enzyme in the 
cholesterol biosynthetic pathway. The enzyme HMG- CoA reductase catalyzes the 
Conversion of HMG-CoA to Mevalonate.
The main mechanism of reduction of Low Density Lipoprotein (LDL) Cholesterol is 
that following inhibition of HMG CoA reductase activity. The LDL receptor density 
on the liver cell is increased (up regulation) and this leads to increased removal of 
LDL cholesterol from the plasma and increased catabolism of LDL Cholesterol. In 
addition there is a reduction in the very low density lipoprotein (VLDL) cholesterol 
and reduced formation of LDL from VLDL. The precursor HMG-CoA is readily 
metabolized back to acetyl CoA.
Pharmacokinetic properties:
                                    Simvastatin is orally administered Prodrug, after oral 
administration, Simvastatin is well absorbed (≈60 to 80%) but undergoes extensive 
first pass metabolism.  In the Liver, Simvastatin is rapidly hydrolysed from the 
inactive lactone form the corresponding to the active  -hydroxyacid metabolite and 
other less important metabolites.
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Simvastatin and its active metabolites are predominantly concentrated in the 
liver, which is the main target site of the drug. Circulating Simvastatin and its active 
β-hydroxyacid metabolite are about 95% bound to plasma proteins. The elimination 
half-life of the major active metabolite is 1.9 hours and total body clearance is 
31.8L/h. approximately 60%of the administered is recovered from the feces, 30% is 
recovered in the urine, almost entirely as inactive metabolites. The pharmacokinetic 
profile of Simvastatin is not affected when the drug is administered immediately 
before a low–fat meal.
Pharmacodynamic properties:
Simvastatin is an inactive prodrug which is hydrolysed in the liver to its major 
active β-hydroxylated metabolite, a competitive and reversible inhibitor of HMG-CoA 
reductase. HMG-CoA reductase is the enzyme responsible for the conversion of 
HMG-CoA to Mevalonic acid, a rate limiting step in the early stages of the 
cholesterol biosynthetic pathway. Inhibition of hepatic  cholesterol biosynthesis by  
HMG-CoA inhibitors give rise to increased expression of low density lipoprotein 
(LDL) receptors in the liver which binds LDL particles and remove from the 
circulation, thereby lowering serum total cholesterol  levels.
Therapeutic use:
                            1. Primary Hypercholesterolaemia (type IIa and IIb) in patients who                      
have not responded adequately to diet and other appropriate measures.
                 2. Coronary heart diseases and elevated plasma cholesterol levels.
Tolerability:                    
Adverse events associated with Simvastatin are mild and transient   and most 
frequently include gastrointestinal problems – Constipation, Diarrhea, Dyspepsia, 
Flatulence, and Nausea. In a large cohort of more than 2400 patients with 
Hypercholesterolemia who participated in a controlled trail and their open extensions, 
Simvastatin was considered to be associated with constipation in 25%, abdominal 
pain in 2.5%, flatulence in 2.0%, and nausea in 1.2% and dyspepsia in 0.7% of 
patients. Other adverse events, which occur in approximately 1 to 3% of patients, 
include headache, sleep disturbances and asthenia. 
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Data from comparative studies indicate that the tolerability profile of 
Simvastatin is similar to that of other HMG-CoA reductase inhibitors and similar or, 
in some cases, tend to be better than that of other agents such as bile acid sequestrants 
or fibrates.
In particular, adverse gastrointestinal effects tend to occur much less 
frequently with Simvastatin then with cholestyramine.
Dosage:    
Simvastatin is administered orally as a single dose in the evening. The 
recommended starting dosage is 5 to 10mg/day which is then titrated according to 
individual response at intervals of at least 4weeks to a maximum dosage of 40mg/day. 
Ramipril: 68
   Ramipril is a lysine derivative of Enalaprilat, the active metabolite of 
Enalapril.
Mechanism of action:
ACE inhibitor Ramipril is a lysine derivative of Enalaprilat; it reduces the 
blood pressure by reducing peripheral vascular resistance without reflexly increasing 
cardiac output, rate or contractility. Ramipril block the Angiotensin converting 
enzyme that cleaves Angiotensin I to form the potent vasoconstrictor, Angiotensin II. 
This inhibitor also diminishes the rate of bradykinin inactivation. Vasodilation occurs 
as a result of the combined effects of lower vasoconstriction caused by diminished 
levels of Angiotensin II and the potent vasodilating effect of increased   bradykinin, 
by reducing circulating Angiotensin II levels. Ramipril also decreases the secretion of   
aldosterone, resulting in decreased sodium and water retention.
Pharmacodynamic properties:
The major action of Ramipril is the reduction in circulating levels of 
Angiotensin II. This is achieved by inhibition of plasma and tissue ACE. Reductions 
in ACE activity in patients receiving Ramipril are related to concentrations of the 
drug in plasma. Maximum reduction in ACE activity occurs 6 to 8 hours after 
administration of a single dose of Ramipril, mediated inhibition of ACE activity 
persists for approximately 12 to 24 hours.
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Various other Neurohormonal mediators e.g. Aldosterone, endothelin, Atrial 
Natriuretic Peptide (ANP) and Bradykinin are involved in the progression and 
symptoms of heart failure. In patients with heart failure, circulating levels of 
vasoconstricting  peptide endothelin-I are also  elevated  increasing with disease 
severity and potentiated by   Angiotensin II, as well as being a potent vasoconstrictor, 
endothelin-I mediates cell proliferation, thus  contributing to cardiac hypertrophy. The 
levels of these mediators are indirectly altered by Ramipril. This is increases 
Bradykinin levels in vitro, possibly through a reduction in Bradykinin degradation, 
and potentiates Bradykinin induced vasodilation.
Administration of Ramipril to patients with heart failure leads to a number of 
improvements in cardiac function:
 Decreases Angiotensin II, Aldosterone and endothelin levels in plasma
 Increases plasma renin levels 
 Increases renal blood flow
 Decreases or no significant change in glomerular filtration rate and decreases 
filtration fraction.
 No effect on plasma catecholamine and adrenalin levels 
 Increases or no change in peak oxygen conception during exercise
Pharmacokinetic properties:
Absorption of orally administered Ramipril is unaffected by food and the 
bioavailability of Ramipril is 25 to 50% in volunteers. In patients with heart failure, 
the absolute bioavailability of Ramipril is reduced approximately 16%. In volunteers 
and patients with heart failure, peak plasma concentration of (Cmax) of l Ramipril after 
oral administration of multiple 2.5 or 5mg doses occur within approximately 6 to 
8hours. Cmax and the area under the curve over the first 96 hours (AUC0-96h) were 
increased in patients with heart failure compared with volunteers.
The drug is not highly plasma protein bound and the volume of distribution is 
124L but this also reduced to a small extent in patients with heart failure. Ramipril
does not undergo metabolism and is excreted unchanged in the urine. Because   of 
reduced   clearance of the drug in patients with heart failure.
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The drug undergo 2 elimination Phases: effective elimination phase and a 
longer terminal elimination phase (which represents binding of the drug to ACE), 
which are ≈12 and 30 hours respectively. The elimination of Ramipril is decreased in 
patients with impaired renal function. Ramipril can be removed by Hemodialysis.
Tolerability: 
         Ramipril is well tolerated by patients with heart failure, and adverse 
events associated with its use usually do not require discontinuation of therapy. The 
most common adverse event was dizziness, occurring in 12% of Ramipril recipients. 
In addition, asthenia, angina pectoris, nausea, dysponea, cough and pruritus occurred 
in Ramipril treated patients but with a similar or lesser incidence then in those treated 
with placebo. In a longer term study of Ramipril in 620 patients the most frequent 
adverse event were Diziness (14%), Dysponea (7.8%), Chest pain (7.5%), Asthenia 
(7.0%), Cough (6.0%), Diarrohoea (6.2%), Hypotension (5.4%) and Nausea (5.2%). 
Dosage: 
A patient with heart failure, the recommended starting dose is 5mg in the US 
or 2.5mg in UK. The dose should be administered once daily and increased to the 
highest dose tolerated by the patient up to a maximum of 20 mg. 
Aspirin: 69
    Most Heart attacks develop when a cholesterol-laden plaque in a coronary 
artery ruptures. Relatively small plaques, which produce only partial blockages, are 
the ones most likely to rupture. When they do, they attract platelets to their surface. 
Platelets are the tiny blood cells that trigger blood clotting. A clot, or thrombus, builds 
up on the ruptured plaque. As the clot grows, it blocks the artery. If the blockage is 
complete, it deprives a portion of the heart muscle of oxygen. As a result, muscle cells 
die-and it’s a heart attack. 
Aspirin helps by inhibiting platelets. Only a tiny amount is needed to inhibit 
all the platelets in the bloodstream; in fact, small amounts are better than high doses. 
But since the clot grows minute by minute, time is of the essence. 
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Pharmacodynamics:
Aspirin affects platelet aggregation by irreversibly inhibiting Prostaglandin 
Cyclooxygenase. This effect lasts for the life of the, platelet and prevents the 
formation of the platelet aggregating factor thromboxane A2.  
Pharmacokinetics:
Aspirin is well and completely absorbed from the gastrointestinal (GI) tract 
and is hydrolyzed to salicylic acid with peak plasma levels of salicylic acid seen 
within 1-2 hours of dosing. The rate of absorption is dependent upon the dosage form, 
the presence or absence of food, gastric pH, and other physiologic factors.  Salicylic 
acid is widely distributed to all tissues and fluids in the body including the Central 
Nervous System (CNS), breast milk and fetal tissues, with highest concentrations seen 
in plasma, liver, renal cortex, heart and lungs. The protein binding of salisylate is    
non-linear at low concentrations (<100mcg/ml), approximately 90% is bound to 
albumin while at higher concentrations (>400mcg/ml), only about 75% is bound. 
          Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a 
phenolic glucouronide, and a number of minor metabolites. The half life of salicylic 
acid is approximately 6 hours. Salicylate metabolism is saturable and total body 
clearance decreases at higher serum concentration due to limited ability of the liver to 
form salicyluric acid and phenolic glucuronide. Following toxic doses (10-20gm), the 
plasma half-life may be increased to over 20 hours. The elimination of salicylic acid 
follows zero order pharmacokinetics. Renal excretion of unchanged drug depends 
upon urine pH. As urinary pH rises above 6.5, the renal clearance of free salicylate 
increases from < 5%   > 80%.
Hydrochlorothiazide:
Clinical Pharmacology: 70
Hydrochlorothiazide is a Thiazide diuretic. The Thiazides are moderately 
potent diuretics which act at the proximal end of the distal tubule causing a decrease 
in reabsorption of electrolytes and an increase in excretion of sodium and chloride 
ions with accompanying water loss. 
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The hypotensive effect is possibly due to a decrease in peripheral resistance. 
They are generally not effective in adults with a creatinine clearance of < 30ml/min.
The proposed mechanism of anti- hypertensive action is:71
1. Initially the diuresis reduces plasma and extracellular fluid volume about 15% 
this reduces cardiac output.
2. Subsequently compensatory mechanisms operate to almost regain NA+
balance and plasma volume; cardiac output is restored, but the fall in BP is 
maintained a slowly developing reduction in total peripherial resistance.
3. The reduction in total peripherial resistance is most probably an indirect 
consequence of a small (5%) persisting NA+  and volume deficit. Decrease in 
intracellular NA+ concentration in the vascular smooth muscle may decrease 
stiffness of vessel wall, increase their compliance and dampen responsiveness 
to constrictor stimuli (NA, AII). Similar effects are produced by salt 
restriction; anti-hypertensive action of diuretics is lost when salt intake is high. 
A mild slowly developing vasodilator action of thiazides has been produced, 
but does not appear to be real. The fall in BP develops gradually over 2-4 
weeks.
Pharmacokinetics: 72  
Hydrochlorothiazide is fairly rapidly absorbed from the gastrointestinal tract 
with a bioavailability of 65 – 70 % (adults), a half life is 5 to 15 hours (adults) and is 
predominantly bound to red blood cells. Elimination half life is dependent on 
glomerular filtration rate (creatinine clearance) and is longer than for chlorothiazide. 
It is excreted mainly unchanged in the urine.
Adverse Effects:  
1. Hypokalaemia, hypochloraemic alkalosis, hypomagnesaemia, hypocalcaemia, 
hypophosphotaemia, hyponatraemia, hyperglycaemia, hyperuricaemia.
2. Small increase in excretion of bicarbonate due to decrease in carbonic-
anhydrase activity.
3. Zinc deficiency.
4. Possibly kernicterus in very jaundiced babies. 
5. Plasma albumin binding sites.
47
Dosage :  
Hydrochlorothiazide comes as a tablet and liquid to take by mouth. It usually 
is taken once or twice a day. If you are to take it once a day, take it in the morning; if 
you are to take it twice a day, take it in the morning and in the late afternoon to avoid 
going to the bathroom during the night. Take this medication with a meal or snack. 
Follow the directions on your prescription label carefully, and ask your doctor or 
pharmacist to explain any part you do not understand. Take hydrochlorothiazide 
exactly as directed. Do not take more or less of it or take it more often than prescribed 
by your doctor.
Hydrochlorothiazide controls high blood pressure but does not cure it. 
Continue to take hydrochlorothiazide even if you feel well. Do not stop taking 
hydrochlorothiazide without talking to your doctor.
Atenolol:
Atenolol is classified as a β1-selective (or 'cardioselective') drug, one that 
exerts greater blocking activity on myocardial β1-receptors than on β2 receptors in the 
lung. The β2 receptors are responsible for keeping the bronchial system open. If these 
receptors are blocked, bronchospasm with serious lack of oxygen in the body can 
result. However, due to its cardioselective properties, the risk of bronchospastic 
reactions if using atenolol is reduced compared to nonselective drugs as propranolol. 
Nonetheless, this reaction may also be encountered with atenolol at high doses. 
Although traditionally β-blockers have been contraindicated when a person carries a 
diagnosis of asthma, recent studies have revealed that at moderate doses selective β-
blockers such as Atenolol are well tolerated.
Therapeutic use and Dosage :
Atenolol may be indicated for the following conditions at specific recommended 
doses. The prescription may vary and should be followed.
High blood pressure
Depending on the patient's individual response, 25 to 100 milligrams may be 
given daily as a single dose. It may take 1 to 2 weeks to observe full effect.
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Chest pains
In single or divided doses, 50 to 100 milligram tablets may be given; this 
must not exceed 200 milligrams a day.
Prevention of migraine
To prevent migraine headaches, 50 to 100 milligrams may be given daily.
Emergency treatment of erratic heart beats
Once diagnosed, 2.5 milligrams may be injected intravenously at 1 milligram 
per minute. It may be repeated every 5 minutes if needed but must not exceed 10 
milligrams. Other doctors may opt to infuse 150 micrograms of the drug for every 
kilo of body weight in 20 minutes. The injection or the infusion may be repeated 
every 12 hours as needed. Once the heart retains its rhythm, oral dose is given at 
50 to 100 milligrams per day.
Heart attack
The drug may be given intravenously within 12 hours after chest pain starts. 
Initial dose of 5 to 10 milligrams is slowly injected at a rate of 1 milligram per 
minute. This can be followed by an oral dose of 50 milligrams after 15 minutes. 
Other physicians may opt to repeat the IV dose of 50 milligrams, 10 minutes after 
the last injection and then give 50 mg tablets after 12 hours. Either way, the 
maintenance dose will be 50 milligrams every 12 hours or 100 milligrams for 6 to 
9 days after the heart attack.
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RESULTS
         The total numbers of patients enrolled were 30 as per the inclusion 
criteria of the study. All the patients were found to be complaint as per the study 
protocol except for three subjects, they were withdrawn from the study (patient no.5 
and 23) due to his absence from visits 2, 3, 4 and one patient (patient no 10) was 
withdrawn from the study due to the adverse event. The total number of patients 
successfully completed the study were 27 as per the inclusion and exclusion criteria. 
            
The total 27 patients were divided in to 2 groups Moderate (Systolic                    
BP 139-159) and Severe (Systolic Bp >159) hypertensive patients according to their 
blood pressure levels. Out of 30 patients 23 patients are under Moderate Hypertensive 
and 4 No of patients under severe hypertensive patients. 
Visit1 Moderate and Severe hypertensive patient’s systolic and diastolic,   
LDL-C, Triglycerides, Total Cholesterol and HDL levels are compared with mean of 
visit 2, 3, 4. These comparisons are represented in the figures. 
50
Table – 1: Moderate Systolic Hypertensive Patients Data
  
Figure 1:  Moderate Systolic Hypertensive Patients Data
Moderate Systolic Hypertensive Patients Data
(mm of Hg)
S.NO
Patient 
no visit1 visit2 visit3 visit4 Mean of visit 2,3&4
1 1 150 140 140 140 140
2 4 150 140 140 130 136.6
3 7 150 140 130 140 136.6
4 8 140 130 130 120 126.6
5 9 150 140 140 140 140
6 10 150 140 140 140 140
7 11 140 120 120 120 120
8 12 140 120 130 130 126.6
9 14 140 120 120 120 120
10 15 150 140 140 130 136.6
11 16 150 160 150 120 143.3
12 17 140 130 130 130 130
13 18 150 140 160 140 146.6
14 19 150 140 130 150 140
15 20 140 150 150 130 143.3
16 22 140 130 140 150 140
17 23 140 130 130 130 130
18 24 140 140 130 130 133.3
19 25 140 140 120 130 130
20 26 140 140 140 140 140
21 27 150 140 130 140 136.6
22 28 140 140 140 130 136.6
23 29 150 150 150 130 143.3
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Table – 2:  Moderate Diastolic Hypertensive Patients Data
Figure – 2: Moderate Diastolic Hypertensive Patients Data
Moderate  Diastolic  Hypertensive Data
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Moderate  Diastolic Hypertensive Patients Data
(mm of Hg)
SE.NO Patient no Visit1 visit2 visit3 visit4 Mean of visit 2,3&4
1 1 100 90 80 80 83.3
2 4 100 100 90 100 96.6
3 7 100 100 80 90 90
4 8 90 80 80 80 80
5 9 90 90 90 80 86.6
6 10 90 90 90 90 90
7 11 90 80 80 90 83.3
8 12 100 80 80 80 80
9 14 100 80 80 80 80
10 15 100 100 90 90 93.3
11 16 100 90 90 70 83.3
12 17 100 80 90 80 86.6
13 18 100 100 100 100 100
14 19 100 90 90 90 90
15 20 90 90 90 100 93.3
16 22 100 90 90 90 90
17 23 90 90 80 80 83.3
18 24 100 90 90 90 90
19 25 100 90 80 90 86.6
20 26 100 100 100 100 100
21 27 90 80 90 80 86.6
22 28 100 100 90 90 93.3
23 29 100 90 90 80 86.6
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Table – 3:  Moderate Hypertensive Patients LDL-C Levels
Moderate Hypertensive Patients LDL-C Levels
S.NO Patient no
visit 
1 visit2 visit3 visit4 Mean of visit 2,3&4
1 1 136 98 82 100 93.3
2 4 161 140 130 104 124.6
3 7 133 84 87 96 89
4 8 84 84 101 94 83
5 9 160 101 124 76 100.3
6 10 138 127 53 136 105.3
7 11 139 121 160 121 107.3
8 12 133 105 117 116 112.6
9 14 162 73 66 80 73
10 15 173 57 120 99 92
11 16 186 147 108 125 126.6
12 17 144 120 114 106 113.3
13 18 156 112 104 112 109.3
14 19 141 112 104 112 109.3
15 20 193 84 79 105 89.3
16 22 189 107 122 120 116.3
17 23 186 106 129 132 122.3
18 24 143 65 128 109 100.6
19 25 130 72 162 85 106.3
20 26 148 121 46 78 81.6
21 27 152 67 134 98 99.6
22 28 130 88 140 110 112.6
23 29 147 101 113 88 100.6
Figure – 3: Moderate Hypertensive Patients LDL-C Levels
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Table – 4: Moderate Hypertensive Patients Triglyceride Levels
Moderate Hypertensive Patients Triglyceride Levels
S.NO Patient no
visit 
1 visit2 visit3 visit4 Mean of visit 2,3&4
1 1 256 187 220 172 193
2 4 243 173 173 158 168
3 7 208 180 185 167 177.3
4 8 247 220 225 169 204.6
5 9 230 198 180 172 183.3
6 10 225 205 153 143 167
7 11 182 164 156 123 147.6
8 12 142 124 128 118 123.3
9 14 184 162 62 68 97.3
10 15 153 145 138 130 137.6
11 16 317 224 240 243 235.6
12 17 206 185 236 101 174
13 18 167 96 158 133 129
14 19 111 90 94 89 91
15 20 126 105 121 88 104.6
16 22 189 134 140 155 143
17 23 299 109 311 144 188
18 24 152 109 115 116 113.3
19 25 89 80 97 54 77
20 26 140 80 137 133 116.6
21 27 354 132 228 142 167.3
22 28 393 231 217 241 229.6
23 29 199 197 156 121 158
Figure – 4: Moderate Hypertensive Patients Triglyceride Levels
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Table – 5: Moderate Hypertensive Patients Total Cholesterol levels
Figure – 5: Moderate Hypertensive Patients Total Cholesterol levels
Moderate Hypertensive Cholesterol Levels
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Moderate Hypertensive Patients Total Cholesterol levels
S.NO Patient no
visit 
1 visit2 visit3 visit4 Mean of visit 2,3&4
1 1 213 154 154 172 160
2 4 216 192 187 141 173.3
3 7 195 141 132 148 140.3
4 8 135 135 145 122 134
5 9 230 152 211 172 178.3
6 10 193 171 122 210 167.6
7 11 216 196 235 198 209.6
8 12 190 161 146 167 158
9 14 226 137 112 148 132.3
10 15 227 238 176 181 198.3
11 16 253 209 183 205 199
12 17 177 180 177 160 172.3
13 18 231 183 141 169 164.3
14 19 218 179 182 209 190
15 20 253 138 133 163 144.6
16 22 262 165 195 188 182.6
17 23 255 169 216 196 193.6
18 24 200 118 184 163 155
19 25 186 118 256 142 172
20 26 222 182 146 148 158.6
21 27 258 167 185 148 166.6
22 28 225 207 177 149 177.6
23 29 224 172 177 156 168.3
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Table – 6: Moderate Hypertensive Patients HDL levels
Figure – 6: Moderate Hypertensive Patients HDL levels
Moderate Hypertensive HDL Levels
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Moderate Hypertensive HDL Levels
S.NO Patient No
Visit 
1 visit2 visit3 visit4 Mean of visit 2,3&4
1 1 33 36 48 56 46.6
2 4 38 48 52 63 54.3
3 7 40 38 42 56 45.3
4 8 28 28 26 31 28.3
5 9 49 42 65 67 58
6 10 34 43 57 67 55.6
7 11 59 60 67 73 66.6
8 12 31 45 42 56 51
9 14 41 40 42 55 45.6
10 15 33 27 43 56 42
11 16 28 40 45 44 43
12 17 36 40 40 58 46
13 18 55 59 56 62 59
14 19 61 54 74 68 65.3
15 20 42 55 62 64 60.3
16 22 46 38 48 62 49.3
17 23 41 43 42 57 47.3
18 24 35 36 37 42 38.3
19 25 46 43 61 48 50.6
20 26 50 53 56 62 57
21 27 43 46 53 57 52
22 28 29 32 31 31 31.3
23 29 54 53 50 51 51.3
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Table – 7:  Severe Systolic Hypertensive Patients Data
Figure – 7:  Severe Systolic Hypertensive Patients Data
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Table – 8:  Severe Diastolic Hypertensive Patients Data
Figure – 8:  Severe Diastolic Hypertensive Patients Data
Severe Diastolic Hypertensive Data
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Severe  Systolic Hypertensive Patients Data
SE.NO Patient no Visit1 visit2 visit3 visit4 Mean of visit 2,3&4
1 2 160 150 130 130 136.6
2 5 160 140 120 130 130
3 6 160 150 130 130 136.6
4 13 160 130 160 130 140
Severe Diastolic Hypertensive Patients Data
SE.NO Patient no Visit1 visit2 visit3 visit4 Mean of visit 2,3&4
1 2 110 100 90 85 91.6
2 5 100 80 80 90 83.3
3 6 100 90 90 90 90
4 13 110 90 82 76 82.6
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Table – 9: Severe Hypertensive Patients LDL-C Levels
Severe Hypertensive Patients LDL-C Levels
SE.NO
Patient 
No Visit1 visit2 visit3 visit4 Mean of visit 2,3&4
1 2 213 178 206 152 181
2 5 236 184 198 178 186.6
3 6 209 172 153 169 164.6
4 13 228 232 197 156 195
                         
Figure – 9:  Severe Hypertensive Patients LDL-C Levels
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Table – 10: Severe Hypertensive Patients Triglyceride Levels
Severe Hypertensive Patients Triglyceride Levels
SE.NO Patient no Visit1 visit2 visit3 visit4 Mean of visit 2,3&4
1 2 154 67 134 98 99.6
2 5 166 109 125 127 120.3
3 6 147 95 89 75 86.3
4 13 157 98 81 94 91
Figure – 10: Severe Hypertensive Patients Triglyceride Levels
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Table – 11: Severe Hypertensive Patients Total Cholesterol Levels
Figure – 11: Severe Hypertensive Patients Total Cholesterol Levels
Severe Hypertensive Cholesterol Levels
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Table – 12: Severe Hypertensive Patients HDL levels
Severe Hypertensive Patients HDL levels
SE.NO Patient no Visit1 visit2 visit3 visit4 Mean of visit 2,3&4
1 2 43 44 55 52 47
2 5 35 46 45 49 46.6
3 6 36 53 62 67 60.6
4 13 28 32 37 42 37
Figure – 12: Severe Hypertensive Patients HDL levels
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Severe Hypertensive Patients Total Cholesterol Levels
SE.NO Patient no Visit1 visit2 visit3 visit4 Mean of visit 2,3&4
1 2 223 120 145 147 137.3
2 5 238 171 185 198 184.6
3 6 202 143 136 128 135.6
4 13 204 149 123 145 139
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Table – 13: Efficacy of Combination Pill on Hypertension
n  values are given as mean ±SEM
**, *** Values are statistically significant compared to Visit 1(Base line) at P<0.01, P<0.001 respectively
                                                                 
Systolic Hypertension Diastolic Hypertension
Moderate Hypertension
(n = 23)
Visit-1 Mean of Visit 2,3,and 4 Visit-1 Mean of Visit 2,3,and 4
144.78 ± 1.065 137.08 ±2.172** 96.96 ±0.981 88.67 ± 1.235***
Severe Hypertension
(n=4)
160.0 ±0.00 135.8 ±2.09*** 105.0 ± 2.88 86.87 ± 2.29**
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Table – 14: Efficacy of Combination Pill on Hyperlipidemia
LDL-C Triglycerides Total Cholesterol HDL
Visit-1
Mean of Visit 
2,3and4
Visit-1
Mean of Visit 
2,3and4
Visit-1
Mean of Visit 
2,3and4
Visit-1
Mean of Visit 
2,3and4
Moderate 
Hypertensiv
e
(n=23)
150.60±5.119
102.96±2.936**
*
209.21±16.047 153.30±8.95** 217.60±6.25 169.4±4.30*** 41.39±2.04 49.73±1.99**
Severe 
Hypertensiv
e
(n=4)
221.5±6.33 181.8±6.414** 156.0±3.93 99.3±7.52*** 216.75±8.51 149.12±11.8** 35.50±3.06 57.9±3.64**
n values are given as mean ±SEM
**, *** Values are statistically significant compared to Visit 1(Base line) at P<0.01, P<0.001 respectively
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DISCUSSION
The efficacy of combination pill on Moderate Systolic Hypertensive patients 
was shown that P<0.05 (P=0.003). The combination pill was considered as effective. 
So the combination pill show higher efficacy the drug has decreased the Systolic 
Blood Pressure higher level and doesn’t  shown any side effects during the 4 visits.
The efficacy of combination pill on Moderate Diastolic Hypertensive patients 
was shown that P<0.05 (P=0.001). The combination pill was considered as effective. 
So the combination pill show higher efficacy the drug has decreased the Diastolic 
Blood Pressure higher level and doesn’t  shown any side effects during the 4 visits.
The efficacy of combination pill on Moderate Hypertensive patients Total 
Cholesterol Levels in patients was shown that P<0.05 (P=0.001). The combination 
pill was considered as effective. So the combination pill show higher efficacy the drug 
has decreased the Cholesterol higher level and doesn’t show any side effects during 
the 4 visits.
The efficacy of combination pill on Moderate Hypertensive patients LDL-C 
Levels in patients was shown that P<0.05 (P=0.001). The combination pill was 
considered as effective. So the combination pill show higher efficacy the drug has 
decreased the LDL-C higher level and doesn’t show any side effects during the 4 
visits.
The efficacy of combination pill on Moderate Hypertensive patients 
Triglyceride Levels in patients was shown that P<0.05 (P=0.004). The combination 
pill was considered as effective. So the combination pill show higher efficacy the drug 
has decreased the Triglyceride Levels higher level and doesn’t show any side effects 
during the 4 visits.
The efficacy of combination pill on Moderate Hypertensive patients HDL 
Levels in patients was shown that P<0.05 (P=0.005). The combination pill was 
considered as effective. So the combination pill show higher efficacy the drug has 
increased the HDL Levels higher level and doesn’t show any side effects during the 4 
visits.
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The efficacy of combination pill on Severe Systolic Hypertensive patients was 
shown that P<0.05 (P=0.001). The combination pill was considered as effective. So 
the combination pill show higher efficacy the drug has decreased the Systolic Blood 
Pressure higher level and doesn’t  shown any side effects during the 4 visits.
The efficacy of combination pill on Severe Diastolic Hypertensive patients 
was shown that P<0.05 (P=0.003). The combination pill was considered as effective. 
So the combination pill show higher efficacy the drug has decreased the Diastolic 
Blood Pressure higher level and doesn’t  shown any side effects during the 4 visits.
The efficacy of combination pill on Severe Hypertensive Cholesterol Levels in 
patients was shown that P<0.05 (P=0.004). The combination pill was considered as 
effective. So the combination pill show higher efficacy the drug has decreased the 
Cholesterol higher level and doesn’t show any side effects during the 4 visits.
The efficacy of combination pill on Severe Hypertensive LDL-C Levels in 
patients was shown that P<0.05 (P=0.005). The combination pill was considered as 
effective. So the combination pill show higher efficacy the drug has decreased the 
LDL-C higher level and doesn’t show any side effects during the 4 visits.
The efficacy of combination pill on Severe Hypertensive Triglyceride Levels 
in patients was shown that P<0.05 (P=0.001). The combination pill was considered as 
effective. So the combination pill show higher efficacy the drug has decreased the 
Triglyceride Levels higher level and doesn’t show any side effects during the 4 visits.
The efficacy of combination pill on Severe Hypertensive HDL Levels in 
patients was shown that P<0.05 (P=0.003). The combination pill was considered as 
effective. So the combination pill show higher efficacy the drug has increased the 
HDL Levels higher level and doesn’t show any side effects during the 4 visits.
The safety of combination pill on Moderate and Severe Hypertensive patients 
laboratory investigations show there is no increase in the SGOT, SGPT, Serum 
Creatinine and Serum electrolytes levels so the combination pill was consider as safe. 
The combination pill show higher safety. 
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CONCLUSION
The efficacy of Ramipril and Simvastatin, Aspirin, Hydrochlorothiazide 
combination was assessed by mean decrease in blood pressure, LDL-C, TG and Total
Cholesterol level the therapy also increased HDL levels after Visit 1(screening) by 
application of suitable statistical parameters ANOVA. The total numbers of patients 
enrolled were 30 as per the inclusion and exclusion criteria of the study. 
          
           All the patients were found to be complaint as per the study protocol except for 
three subjects, who was withdrawn from the study (patient No.3 and 21) due to his 
absence from visits 2, 3, 4 and one patient (patient No 30) was withdrawn from the
study due to the adverse event ( Severe Dry Cough). The total number of patients 
successfully completed the study were 27 as per the inclusion and exclusion criteria. 
         Result of the present study suggest a significant decrease in the all the efficacy 
parameters (p<0.005) concluding that the drug combination has effective in 
decreasing the blood pressure and LDL-C levels.
The safety parameters were assessed by concentrating on the adverse drug 
event during the 4 visits. 
Therefore, the drug combination Rampril (5mg), Simvastatin (20mg) ,Aspirin 
(100mg), Atenolol (50mg) and Hydrochlorothiazide (12.5mg) was found to have 
maximum safety with minimum adverse events reported, which is helpful in treatment 
of patients with hypertension and Dyslipidemia or coronary artery diseases. 
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APPENDIX
QUESTIONAIRE:
Patient Demography:
Age:----------- Sex: M/ F Weight (kg):----------- Height (cm):------
Marital Status: Single □ Married  □ Divorced □ Widow/Widower  □
Educational status: ---------------------------------
Employment status: employed □ unemployed  □
1. When was your‚ high BP‛ diagnosed?
Date (year) □ Don’t know □
2. What was your blood pressure reading at diagnosis? Reading:
Don’t know □
3. How long did it take you to start antihypertensive management?
Immediately □
1-3mths □ 4-6mths □ 7mths-1year □
other (specify) ___________
4. How long has it been since you started antihypertensive management?
1-3mths □ 4-6mths □ 7mths-1year □ 
other (specify) ___________
5. How many antihypertensive medicines did you start with?
1 2 3 ≥4 (specify) ___________. 
Don’t remember □
6. Please provide details of your initial antihypertensive management. Include
names of medication, dosage and how often taken.
Class of AHA Name of specific drug
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A. Diuretics (DIU) □
B. Angiotensin- Converting Enzyme Inhibitors (ACEI) □
C. Calcium channel blockers (CCB) □
D. Angiotensin II receptor blockers (ARB) □
E. Beta- blockers (BB) □
F. Centrally acting agents (CAA) □
G. Vasodilators (VAS) □
H. Alpha blockers (AB) □
7. Please provide details of your current antihypertensive management. Include
names of medication, dosage and how often taken.
Class of AHA Name of specific drug
Diuretics (DIU) □
Angiotensin-Converting Enzyme Inhibitors (ACEI) □
Calcium channel blockers (CCB) □
Angiotensin II receptor blockers (ARB) □
Beta- blockers (BB) □
Centrally acting agents (CAA) □
Vasodilators (VAS) □
Alpha blockers (AB) □
8. What is your BP presently? Reading
9. Has your antihypertensive management changed since initial diagnosis?
Yes No
10. How many times has your drugs been changed? Once Twice
Thrice ≥ 4
73
11. Why were the medications changed?
Side effects □
not reaching a goal BP  □
unavailability of drugs  □
Personal request    □
12. Please list all other medication(s), not previously mentioned in this questionnaire, 
that you are taking regularly or intermittently whether for this or any other 
condition/illness.
Name of specific drug
13. How often do you visit the Clinic in a year?
1 2 3 ≥ 4 (specify) ___________
14. What side effects do you experience since taking the antihypertensive 
medications?
Headache /Drowsiness/ Fatigue /Cough/ Fluid Retention/ Nausea/vomiting 
/Decreased sex drive Diarrhea/constipation/ Flushing/ Dizziness /Body 
weakness/Decreased sense of taste/ loss of appetite/ erectile dysfunction
Others (specify) ----------------------------------------------
15. Anti-platelet drug Prescribed: ---------------------------------------
16. Hypolidemic agent Prescribed: ------------------------------------
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